Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II study of TAS-114 in combination with S-1 in patients with advanced gastric cancer refractory to prior chemotherpy.

Trial Profile

Phase II study of TAS-114 in combination with S-1 in patients with advanced gastric cancer refractory to prior chemotherpy.

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Jan 2019

At a glance

  • Drugs TAS 114 (Primary) ; Gimeracil/oteracil/tegafur
  • Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
  • Focus Therapeutic Use
  • Acronyms TAS114_GC study
  • Most Recent Events

    • 07 Jan 2019 According to UMIN, the anticipated date for data entry closure is 31 Jan 2019, and the date for conclusion of data analysis is 1 May 2020.
    • 07 Jan 2019 Status changed from suspended to completed.
    • 19 Sep 2018 Status changed from recruiting to suspended.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top